Inverse correlation between plasma 2-arachidonoylglycerol levels and subjective severity of depression.
2-AG
AEA
depression
endocannabinoids
escitalopram
Journal
Human psychopharmacology
ISSN: 1099-1077
Titre abrégé: Hum Psychopharmacol
Pays: England
ID NLM: 8702539
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
14
01
2021
received:
01
06
2020
accepted:
15
01
2021
pubmed:
10
2
2021
medline:
27
1
2022
entrez:
9
2
2021
Statut:
ppublish
Résumé
Endocannabinoids have been implicated in the pathophysiology of Major Depressive Disorder (MDD) and might represent potential targets for therapeutic intervention. Objectives of the study were: (1) to measure plasma levels of endocannabinoids in a group of antidepressant-free depressed outpatients; (2) to explore their relationship with the severity of depressive symptoms as subjectively perceived by the patients; and (3) to investigate the effect of the selective serotonin reuptake inhibitor escitalopram on endocannabinoid levels. We measured plasma levels of the two major endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anadamide), in 12 drug-free outpatients diagnosed with MDD and in 12 matched healthy controls. In the patient group, endocannabinoids plasma levels were assessed at baseline and after 2 months of treatment with escitalopram. Baseline plasma levels of the two endocannabinoids did not differ between depressed patients and healthy controls. However, there was a significant inverse correlation between 2-arachidonoylglycerol levels and the severity of subjectively perceived depressive symptoms. Treatment with escitalopram did not change endocannabinoid levels in depressed patients, although it caused the expected improvement of depressive symptoms. Our results suggest that 2-arachidonylglycerol, the most abundant endocannabinoid in the central nervous system, might act to mitigate depressive symptoms, and raise the interesting possibility that 2-arachidonylglycerol and anandamide are differentially regulated in patients affected by MDD. Also, our data suggest but do not prove that the endocannabinoid system is not regulated by serotonergic transmission, at least in depressed patients.
Substances chimiques
Arachidonic Acids
0
Endocannabinoids
0
Glycerides
0
Escitalopram
4O4S742ANY
glyceryl 2-arachidonate
8D239QDW64
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2779Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Aso, E., Ozaita, A., Valdizán, E. M., Ledent, C., Pazos, Á., Maldonado, R., & Valverde, O. (2008). BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice. Journal of Neurochemistry, 105(2), 565-572. https://doi.org/10.1111/j.1471-4159.2007.05149.x
Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Archives of General Psychiatry, 4(6), 561-571. https://doi.org/10.1001/archpsyc.1961.01710120031004
Bersani, G., & Iannitelli, A. (2015). Legalization of cannabis: Between political irresponsibility and loss of responsibility of psychiatrists. Rivista di Psichiatria, 50(5), 195-198. https://doi.org/10.1708/2040.22156
Chadwick, V. L., Rohleder, C., Koethe, D., & Leweke, F. M. (2020). Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Current Opinion in Psychiatry, 33(1), 20-42. https://doi.org/10.1097/YCO.0000000000000562
Fanelli, F., Di Lallo, V. D., Belluomo, I., De Iasio, R., Baccini, M., Casadio, E., & Pagotto, U. (2012). Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. Journal of Lipid Research, 53(3), 481-493. https://doi.org/10.1194/jlr.M021378
Ghonghadze, M., Pachkoria, K., Okujava, M., Antelava, N., & Gongadze, N. (2020). Endocannabinoids receptors mediated central and peripheral effects (review). Georgian Medical News, 298, (1), 137-143.
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006). Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Research, 1071(1), 10-23. https://doi.org/10.1016/j.brainres.2005.11.035
Gorzalka, B. B., & Hill, M. N. (2006). Cannabinoids, reproduction, and sexual behavior. Annual Review of Sex Research, 17(1), 132-161. https://doi.org/10.1080/10532528.2006.10559840
Gorzalka, B. B., Hill, M. N., & Chang, S. C. H. (2010). Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Hormones and Behavior. https://doi.org/10.1016/j.yhbeh.2009.08.009
Hauer, D., Schelling, G., Gola, H., Campolongo, P., Morath, J., Roozendaal, B., & Kolassa, I. T. (2013). Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder. PLoS One, 8(5), e62741. https://doi.org/10.1371/journal.pone.0062741
Hill, M. N., & Gorzalka, B. B. (2005). Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behavioural Pharmacology, 16, 333-352. https://doi.org/10.1097/00008877-200509000-00006
Hill, M. N., & McEwen, B. S. (2010). Involvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoids. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(5), 791-797. https://doi.org/10.1016/j.pnpbp.2009.11.001
Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009). Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology, 34(8), 1257-1262. https://doi.org/10.1016/j.psyneuen.2009.03.013
Hill, M. N., Miller, G. E., Ho, W. S. V., Gorzalka, B. B., & Hillard, C. J. (2008). Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report. Pharmacopsychiatry, 41(2), 48-53. https://doi.org/10.1055/s-2007-993211
Hill, M. N., & Patel, S. (2013). Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biology of Mood & Anxiety Disorders, 3(1), 19. https://doi.org/10.1186/2045-5380-3-19
Hungund, B. L., Vinod, K. Y., Kassir, S. A., Basavarajappa, B. S., Yalamanchili, R., Cooper, T. B., & Arango, V. (2004). Upregulation of CB1 receptors and agonist-stimulated [35S] GTPγS binding in the prefrontal cortex of depressed suicide victims. Molecular Psychiatry, 9(2), 184-190. https://doi.org/10.1038/sj.mp.4001376
Iannitelli, A., Quartini, A., Tirassa, P., & Bersani, G. (2017). Schizophrenia and neurogenesis: A stem cell approach. Neuroscience and Biobehavioral Reviews, 80, 414-442. https://doi.org/10.1016/j.neubiorev.2017.06.010
Kamprath, K., Marsicano, G., Tang, J., Monory, K., Bisogno, T., Di Marzo, V., & Wotjak, C. T. (2006). Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. Journal of Neuroscience, 26(25), 6677-6686. https://doi.org/10.1523/JNEUROSCI.0153-06.2006
Kirkedal, C., Elfving, B., Müller, H. K., Moreira, F. A., Bindila, L., Lutz, B., & Liebenberg, N. (2019). Hemisphere-dependent endocannabinoid system activity in prefrontal cortex and hippocampus of the flinders sensitive line rodent model of depression. Neurochemistry International, 125, 7-15. https://doi.org/10.1016/j.neuint.2019.01.023
Lazary, J., Eszlari, N., Juhasz, G., & Bagdy, G. (2019). A functional variant of CB2 receptor gene interacts with childhood trauma and FAAH gene on anxious and depressive phenotypes. Journal of Affective Disorders, 257, 716-722. https://doi.org/10.1016/j.jad.2019.07.083
Marsicano, G., & Lutz, B. (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. European Journal of Neuroscience, 11(12), 4213-4225. https://doi.org/10.1046/j.1460-9568.1999.00847.x
Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64(1), 21-47. https://doi.org/10.1146/annurev-psych-113011-143739
Mikics, E., Vas, J., Aliczki, M., Halasz, J., & Haller, J. (2009). Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behavioural Pharmacology, 20(3), 265-272. https://doi.org/10.1097/FBP.0b013e32832c70b1
Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., & Huang, Y. (2013). Elevated brain cannabinoid CB 1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Molecular Psychiatry, 18(9), 1034-1040. https://doi.org/10.1038/mp.2013.61
Oropeza, V. C., Mackie, K., & Van Bockstaele, E. J. (2007). Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Research, 1127(1), 36-44. https://doi.org/10.1016/j.brainres.2006.09.110
Poleszak, E., Wośko, S., Sławińska, K., Wyska, E., Szopa, A., Świąder, K., & Serefko, A. (2020). Influence of the endocannabinoid system on the antidepressant activity of bupropion and moclobemide in the behavioural tests in mice. Pharmacological Reports. https://doi.org/10.1007/s43440-020-00088-0
Quarta, C., Mazza, R., Obici, S., Pasquali, R., & Pagotto, U. (2011). Energy balance regulation by endocannabinoids at central and peripheral levels. Trends in Molecular Medicine, 17, 518-526. https://doi.org/10.1016/j.molmed.2011.05.002
Quartini, A., Pacitti, F., Bersani, G., & Iannitelli, A. (2017). From adolescent neurogenesis to schizophrenia: Opportunities, challenges and promising interventions. Biomedical Reviews, 28, 66-73.
Rodríguez-Muñoz, M., Sánchez-Blázquez, P., Callado, L. F., Meana, J. J., & Garzón-Niño, J. (2017). Schizophrenia and depression, two poles of endocannabinoid system deregulation. Translational Psychiatry, 7(12), 1291. https://doi.org/10.1038/s41398-017-0029-y
Sanchis-Segura, C., Cline, B. H., Marsicano, G., Lutz, B., & Spanagel, R. (2004). Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology, 176(2), 223-232. https://doi.org/10.1007/s00213-004-1877-8
Santucci, V., Storme, J. J., Soubrié, P., & Le Fur, G. (1996). Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sciences, 58(5), PL103-PL110. https://doi.org/10.1016/0024-3205(95)02319-4
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., & Dunbar, G. C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl. 20), 22-33.
Smaga, I., Gawlinski, D., Brodowicz, J., & Filip, M. (2019). Brain region-dependent changes in the expression of endocannabinoid-metabolizing enzymes in rats following antidepressant drugs. Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society, 70(5), 1-9. https://doi.org/10.26402/jpp.2019.5.06
Yin, A., Wang, F., & Zhang, X. (2019). Integrating endocannabinoid signaling in the regulation of anxiety and depression. Acta Pharmacologica Sinica, 40, 336-341. https://doi.org/10.1038/s41401-018-0051-5.
Zhou, D., Li, Y., Tian, T., Quan, W., Wang, L., Shao, Q., & Ma, Y. M. (2017). Role of the endocannabinoid system in the formation and development of depression. Pharmazie, 72, 435-439. https://doi.org/10.1691/ph.2017.7474